arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Polidocanol
Mechanistic comparison of arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) [Supplementary Concept] isolated from and Polidocanol based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
6
Shared Targets
20%
Jaccard Similarity
18%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) and Polidocanol share 6 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.200 means 20% of the combined target set is bound by both compounds. The IDF-weighted score of 0.176 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
Related Comparisons
Similar to arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside)
arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs deguelin6 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Etazolate3 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Lumefantrine6 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Thioinosine5 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Itraconazole5 targets